

Oleksandr Kalyuzhniy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4920313/publications.pdf>

Version: 2024-02-01

20
papers

3,871
citations

430874

18
h-index

794594

19
g-index

20
all docs

20
docs citations

20
times ranked

3862
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Highly mutated antibodies capable of neutralizing N276 glycan-deficient HIV after a single immunization with an Env trimer. <i>Cell Reports</i> , 2022, 38, 110485. | 6.4 | 4 |
| 2 | B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22920-22931. | 7.1 | 42 |
| 3 | A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. <i>Science</i> , 2019, 366, . | 12.6 | 172 |
| 4 | Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. <i>Immunity</i> , 2018, 48, 133-146.e6. | 14.3 | 274 |
| 5 | The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. <i>Science Translational Medicine</i> , 2018, 10, . | 12.4 | 113 |
| 6 | Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins. <i>PLoS Pathogens</i> , 2018, 14, e1006986. | 4.7 | 28 |
| 7 | Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. <i>Immunity</i> , 2018, 49, 301-311.e5. | 14.3 | 110 |
| 8 | Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. <i>Nature Communications</i> , 2017, 8, 1655. | 12.8 | 142 |
| 9 | Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design. <i>PLoS Pathogens</i> , 2017, 13, e1006212. | 4.7 | 58 |
| 10 | Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. <i>PLoS Pathogens</i> , 2016, 12, e1005815. | 4.7 | 104 |
| 11 | Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. <i>Science</i> , 2016, 353, 1557-1560. | 12.6 | 147 |
| 12 | Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. <i>Cell</i> , 2016, 166, 1459-1470.e11. | 28.9 | 230 |
| 13 | HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. <i>Immunity</i> , 2016, 45, 483-496. | 14.3 | 335 |
| 14 | Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6849-E6858. | 7.1 | 38 |
| 15 | HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. <i>Science</i> , 2016, 351, 1458-1463. | 12.6 | 382 |
| 16 | Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. <i>Science</i> , 2015, 349, 156-161. | 12.6 | 358 |
| 17 | Proof of principle for epitope-focused vaccine design. <i>Nature</i> , 2014, 507, 201-206. | 27.8 | 451 |
| 18 | Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors. <i>Science</i> , 2013, 340, 711-716. | 12.6 | 680 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Computational Design of Epitope-Scaffolds Allows Induction of Antibodies Specific for a Poorly Immunogenic HIV Vaccine Epitope. <i>Structure</i> , 2010, 18, 1116-1126. | 3.3 | 203 |
| 20 | Highly Mutated Antibodies Capable of Neutralizing N276-Glycan Deficient HIV after a Single Immunization with an Env Trimer. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |